Every 8-K that Compass Therapeutics, Inc. (CMPX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CMPX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CMPX filings page.
Compass Therapeutics, Inc. (CMPX) reported that the FDA has recommended conducting a trial demonstrating an overall survival benefit before proceeding with a Biologics License Application (BLA) for its investigational antibody tovecimig in previously treated, advanced biliary tract cancer. Compass disagrees that a new trial is warranted and plans to further engage with the FDA while continuing BLA preparations.
The company highlights positive Phase 2/3 COMPANION-002 results, where tovecimig plus paclitaxel improved objective response rate to 18.0% versus 5.3% with paclitaxel alone and extended median progression-free survival to 4.7 versus 2.6 months, with a hazard ratio of 0.44, representing a 56% reduction in risk of disease progression. Overall survival did not reach statistical significance due to high crossover from control to tovecimig, and the safety profile was generally consistent with prior studies.
Compass Therapeutics, Inc. reported a deeper net loss while accelerating its oncology pipeline in the quarter and six months ended June 30, 2026. Net loss for the quarter was $25.2 million, or $0.13 per share, versus $19.9 million, or $0.14 per share, a year earlier. Research and development expenses rose to $19.6 million, up 19% year over year, mainly from higher spending on tovecimig, while general and administrative expenses increased to $7.4 million, up 59% on greater pre-commercialization and stock-based compensation costs. Cash and marketable securities totaled $180 million at June 30, 2026, down from $209 million at year-end 2025, and are expected to fund operations into 2028.
The lead candidate tovecimig (DLL4 x VEGF-A bispecific antibody) showed an overall response rate of 18.0% (20/111) in a Phase 2/3 biliary tract cancer study versus 5.3% for paclitaxel, with a p-value of 0.0228, and is being prepared for a potential BLA filing following FDA feedback expected in Q3 2026. The dataset was selected for an oral presentation at the 2026 ESMO Congress, and multiple investigator-sponsored trials are underway in BTC, colorectal cancer, and glioblastoma. CTX-8371 cohort expansions are enrolling patients in several tumors with additional data expected in Q4 2026, CTX-10726 has begun dosing in a multi-dose Phase 1 trial with initial data also expected in Q4 2026, and a Phase 2 trial of CTX-471 in NCAM-expressing tumors is planned to start in Q3 2026.
Compass Therapeutics furnished an updated corporate presentation outlining new clinical data and plans for its oncology pipeline, led by tovecimig for second-line biliary tract cancer (BTC). In the Phase 2/3 COMPANION-002 study, tovecimig plus paclitaxel achieved an overall response rate of 18.0% versus 5.3% with paclitaxel alone and improved median progression-free survival to 4.7 months from 2.6 months. Overall survival analysis was complicated by a 54% crossover from control to the combination, but subset analyses showed longer survival in crossover patients. The company plans an FDA meeting in Q3 2026 and a biologics license application filing in Q4 2026, targeting potential approval in 2027. Compass reports $195 million in cash and marketable securities as of Q1 2026, which it expects will fund operations into 2028 while advancing additional bispecific and CD137 programs.
Compass Therapeutics, Inc. updated its corporate governance by adopting Second Amended and Restated Bylaws, effective June 22, 2026. The new bylaws replace the prior version from July 17, 2020. They establish exclusive jurisdiction in the U.S. District Courts for the District of Delaware and District of Massachusetts for claims arising under the Securities Act of 1933.
Compass Therapeutics, Inc. reported the results of its annual stockholder meeting held on June 10, 2026. Stockholders elected Class III directors Thomas J. Schuetz and Richard S. Lindahl to serve until the 2029 annual meeting. They also ratified CohnReznick LLP as independent registered public accounting firm for the year ending December 31, 2026, with 137,896,097 votes for and 181,037 against. On a non-binding basis, stockholders approved executive compensation, with 117,963,684 votes for and 1,796,022 against, and voted to hold future advisory votes on executive compensation every year, with 118,289,260 votes favoring an annual frequency.
Compass Therapeutics reported first quarter 2026 results and highlighted major progress in its oncology pipeline. Net loss was $18.3 million, or $0.10 per share, compared with $16.6 million, or $0.12 per share, for the same period in 2025. Cash and marketable securities totaled $195 million as of March 31, 2026, which the company expects will fund operations into 2028.
Tovecimig plus paclitaxel in second-line biliary tract cancer achieved an overall response rate of 17.1% versus 5.3% for paclitaxel alone and improved median progression-free survival to 4.7 months versus 2.6 months (HR=0.44, p<0.0001). Tovecimig received Orphan Drug Designation, and the company plans a BLA submission later in 2026. Early signals from CTX-8371 and CTX-10726, along with planned CTX-471 Phase 2 work, underscore a broad bispecific antibody pipeline.
Compass Therapeutics reported detailed results from its randomized Phase 2/3 COMPANION-002 study of tovecimig plus paclitaxel in second-line biliary tract cancer. In 168 patients randomized 2:1, the combination improved overall response rate to 17.1% versus 5.3% for paclitaxel alone, meeting the primary endpoint with statistical significance (p=0.031).
The key secondary endpoint of median progression-free survival also favored tovecimig, with 4.7 months versus 2.6 months for control (hazard ratio 0.44, p<0.0001), based on blinded independent central review. Overall survival analyses did not meet statistical significance because 54% of control patients crossed over to receive tovecimig; these crossover patients showed median overall survival of 12.8 months versus 6.1 months for non-crossover patients (hazard ratio 0.54, p=0.04).
The company stated that tovecimig was generally well tolerated, with a safety profile consistent with prior studies, and noted that 85% of trial participants received the combination. Compass intends to meet with the U.S. FDA in the coming months to discuss the data in advance of a planned Biologics License Application submission for tovecimig in this setting.
Compass Therapeutics reported full-year 2025 results and a broad pipeline update. Net loss was $66.5 million, or $0.42 per share, compared with $49.4 million, or $0.36 per share, in 2024. Research and development expenses rose to $56.0 million, up 32%, mainly from higher manufacturing spend for tovecimig and CTX-10726.
As of December 31, 2025, cash and marketable securities totaled $209 million, up from $127 million a year earlier, giving an expected cash runway into 2028. The company used $49 million in operating cash during 2025, offset by $129 million in net proceeds from an underwritten public offering.
Clinically, lead asset tovecimig met the primary endpoint in the COMPANION-002 Phase 2/3 biliary tract cancer study, with progression-free survival and overall survival analyses expected in April. Expansion cohorts for CTX-8371, IND clearance and Phase 1 initiation for CTX-10726, and a planned Phase 2 trial for CTX-471 position 2026 as an important development year.
Compass Therapeutics, Inc. filed a current report to share that it has released its financial results for the quarter and nine months ended September 30, 2025. The company reported these results via a press release dated November 5, 2025, which is attached to the report as an exhibit and incorporated by reference. The filing is focused on making this earnings information available to the market and does not itself detail the specific revenue, profit, or cash figures.
Compass Therapeutics, Inc. entered an underwriting agreement to sell 33,290,000 shares of common stock at $3.00 per share and pre-funded warrants to purchase up to 6,710,000 shares at $2.9999 per warrant with an exercise price of $0.0001 per share. The underwriters have a 30-day option to purchase up to an additional 6,000,000 shares.
The company estimates net proceeds of approximately $112.5 million (or approximately $129.5 million if the option is exercised in full) and expects closing on or about August 14, 2025. Compass intends to use proceeds to prepare for commercial readiness, fund research and clinical development, and for general corporate purposes, and states that, assuming $112.5 million net proceeds, its cash is expected to fund operations into 2028. The filing notes the company may use capital sooner than expected and will receive nominal proceeds, if any, from exercise of the pre-funded warrants.
Compass Therapeutics furnished a Current Report on Form 8-K announcing that it issued a press release with financial results for the quarter and six months ended June 30, 2025. The press release is included as Exhibit 99.1. The company also furnished the slides presented on its second quarter earnings call as Exhibit 99.2 and its August 2025 corporate presentation as Exhibit 99.3. The filing states that the materials in Item 7.01 (including Exhibit 99.2) are being furnished and not filed, and thus are not subject to Section 18 liabilities or automatically incorporated by reference in other filings. The report discloses the company's common stock trades under the symbol CMPX on the NASDAQ Capital Market. No financial figures are included within the 8-K itself; detailed results are provided in the furnished press release.